Chester County News and Community Website
WILMINGTON, DE — Incyte Corporation (Nasdaq: INCY) announced equity inducement award grants to Bill Meury following his recent appointment as the Company’s new President and CEO. The awards were granted …
Incyte Announces Equity Awards for New CEO Bill Meury with Performance-Based Incentives Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) has named Bill Meury as its new President and Chief Executive Officer (CEO) and elected him to the company’s Board of Directors, effective immediately. …
Bill Meury Named President and CEO of Incyte Read More WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has announced a three-month extension for its review of the supplemental New Drug Application (sNDA) for ruxolitinib cream (Opzelura®), submitted …
FDA Extends Review Period for Ruxolitinib Cream for Pediatric Atopic Dermatitis Read More WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix) in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory …
FDA Approves Monjuvi for Treating Relapsed or Refractory Follicular Lymphoma Read More VENLO, Netherlands & WILMINGTON, DE — QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) have announced a global collaboration to create a next-generation sequencing (NGS) diagnostic …
QIAGEN and Incyte Partner to Develop NGS Diagnostic Panel for Rare Blood Cancers Read More WILMINGTON, DE — First clinical data for INCA033989, a novel monoclonal antibody from Incyte (Nasdaq: INCY) targeting CALR-mutant myeloproliferative neoplasms (MPNs), were presented at the European Hematology Association (EHA) Congress …
Promising Results for Novel Therapy in CALR-Mutant Myeloproliferative Neoplasms Read More WILMINGTON, DE — Groundbreaking results from the Phase 3 POD1UM-303/InterAACT 2 trial have been published in The Lancet, showcasing the efficacy of retifanlimab (Zynyz®) in combination with carboplatin and paclitaxel …
New Phase 3 Trial Data Positions Retifanlimab as Breakthrough in Advanced SCAC Treatment Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced it recently granted restricted stock unit awards (RSUs) totaling 16,550 shares of common stock to 19 new employees. The awards were issued under …
Incyte Awards 16,550 RSUs to New Employees Under 2024 Inducement Plan Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) is set to present pivotal data from its hematology/oncology portfolio at the 2025 European Hematology Association (EHA) Congress, scheduled for June 12–15 in Milan. …
Incyte to Showcase Groundbreaking Hematology/Oncology Data at EHA 2025 Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced its participation in the Goldman Sachs Healthcare Conference, scheduled for Monday, June 9, 2025, at 11:20 AM (ET).
Incyte to Present Live at Goldman Sachs Healthcare Conference 2025 Read More